| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/14/2002 | US20020019530 Antitumor agent |
| 02/14/2002 | US20020019526 Pyrrolo[2,3-d]pyrimidine compounds |
| 02/14/2002 | US20020019425 Anticancer agents; administering p53 gene or protein |
| 02/14/2002 | US20020019418 Methods of preventing breast cancer |
| 02/14/2002 | US20020019415 Cancer treatment |
| 02/14/2002 | US20020019414 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors |
| 02/14/2002 | US20020019404 Anticancer agents, skin disorders |
| 02/14/2002 | US20020019402 Integrin inhibitors and their methods of use |
| 02/14/2002 | US20020019400 Compounds useful for inhibition of farnesyl protein transferase |
| 02/14/2002 | US20020019393 Treating inflammation, autoimmune diseases, destructive bone disorders, proliferative disorders, infections, neurvous system disorders, reperfusion/ischemia in stroke, cardiovascular disorders, hypoxia, edema, fever, pain |
| 02/14/2002 | US20020019382 Curcumin analogs with anti-tumor and anti-angiogenic properties |
| 02/14/2002 | US20020019366 Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives |
| 02/14/2002 | US20020019365 Encapsulation is dissolution resistant at a pH of about 4 to 5 or less and dissolves at a pH of greater than about 4 to 5 |
| 02/14/2002 | US20020019362 Treatment of tumors with genetically engineered herpes virus |
| 02/14/2002 | US20020019346 Treatment of prostate cancer by inhibiting lyn tyrosine kinase |
| 02/14/2002 | US20020019343 Antineoplastic conjugates of transferrin, albumin and polyethylene glycol |
| 02/14/2002 | US20020019030 25324, 50287, 28899, 47007, and 42967 transferase family members and uses therefor |
| 02/14/2002 | US20020019011 Mixture of therapeutic particles for use in the treatment of aging, viral, genetic and cancer diseases |
| 02/14/2002 | US20020019010 Treating aging, viral, genetic and cancer diseases in humans; provide therapeutic particles, generate layout, provide test sample, incubate with sample, monitor sample for reduction in injury associated with defect |
| 02/14/2002 | US20020019000 Polynucleotides coexpressed with matrix-remodeling genes |
| 02/14/2002 | US20020018775 Complexing; separation; gene therapy |
| 02/14/2002 | US20020018769 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| 02/14/2002 | US20020018766 Genes differentially expressed in cancer cells to design cancer vaccines |
| 02/14/2002 | US20020018752 Ablation disease by cutting, blocking blood supply to tissue |
| 02/14/2002 | US20020018750 Anticancer agents |
| 02/14/2002 | DE10036871A1 Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe Dispersions for the formulation of poorly soluble drugs or little |
| 02/14/2002 | CA2775616A1 Salts of benzimidazole compound and application thereof |
| 02/14/2002 | CA2555850A1 Methods of treating cancer and the pain associated therewith using endothelin antagonists |
| 02/14/2002 | CA2453907A1 Association of sim2 with cancer |
| 02/14/2002 | CA2423519A1 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 02/14/2002 | CA2419066A1 Food supplement |
| 02/14/2002 | CA2419060A1 Indole compounds useful for the treatment of cancer |
| 02/14/2002 | CA2418995A1 Lactam compounds and their use as inhibitors of serine proteases and method |
| 02/14/2002 | CA2418899A1 Use of immunogens to treat or prevent malignant breast tumours, immune or vascular system disorders stemming from extra-cellular factors |
| 02/14/2002 | CA2418895A1 Biphenyl derivatives and their use as ppar-gamma receptor activators |
| 02/14/2002 | CA2418445A1 Stress proteins and peptides and methods of use thereof |
| 02/14/2002 | CA2418386A1 Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein |
| 02/14/2002 | CA2418383A1 Radiolabelled metal transport proteins as imaging agents |
| 02/14/2002 | CA2418014A1 Immunotherapy for chronic myelocytic leukemia |
| 02/14/2002 | CA2417994A1 Synthetic salicylihalamides, apicularens and derivatives thereof |
| 02/14/2002 | CA2417967A1 Azabicyclic derivatives and their therapeutic use |
| 02/14/2002 | CA2417930A1 Pharmaceutical compositions containing lithium carbonate |
| 02/14/2002 | CA2417915A1 Her-2/neu fusion proteins |
| 02/14/2002 | CA2417909A1 Isolation and use of solid tumor stem cells |
| 02/14/2002 | CA2417769A1 Drug metabolizing enzymes |
| 02/14/2002 | CA2417676A1 Sequences for integrin alpha-8 |
| 02/14/2002 | CA2417606A1 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 02/14/2002 | CA2417587A1 Transporters and ion channels |
| 02/14/2002 | CA2417358A1 Bio-intermediates for use in the chemical synthesis of polyketides |
| 02/14/2002 | CA2417214A1 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
| 02/14/2002 | CA2417098A1 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | CA2416982A1 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
| 02/14/2002 | CA2416890A1 Therapeutic anti-melanoma compounds |
| 02/14/2002 | CA2416525A1 Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| 02/14/2002 | CA2415469A1 Quinoline derivatives having vegf inhibiting activity |
| 02/14/2002 | CA2415467A1 Novel n-(2-phenyl-3-aminopropyl)naphtamides |
| 02/14/2002 | CA2415333A1 Adenovirus e1b-55k single amino acid mutants and methods of use |
| 02/14/2002 | CA2415022A1 Cinnoline compounds |
| 02/14/2002 | CA2412368A1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 02/14/2002 | CA2411928A1 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclindependent kinases |
| 02/14/2002 | CA2386103A1 Vascular endothelial growth factor 2 |
| 02/13/2002 | EP1179541A1 Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| 02/13/2002 | EP1179353A1 Antithrombogenic implants with coating of polyphosphazenes and a pharmacologically active agent |
| 02/13/2002 | EP1179186A2 Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction |
| 02/13/2002 | EP1179094A2 Assay for the detection of paclitaxel resistant cells in human tumors |
| 02/13/2002 | EP1179093A1 Expression of ets-domain proteins in cancer |
| 02/13/2002 | EP1179066A2 Extracellular signaling molecules |
| 02/13/2002 | EP1179065A2 Full-length molecules expressed in human tissues |
| 02/13/2002 | EP1179064A2 Secreted polypeptides and corresponding polynucleotides |
| 02/13/2002 | EP1179062A2 Nucleic acids and proteins with p53 activity and altered tetramerization domains |
| 02/13/2002 | EP1179061A1 Methods for treating tumors using antiangiogenic compounds |
| 02/13/2002 | EP1179052A2 Serine proteases |
| 02/13/2002 | EP1179019A2 Immunogenic peptides derived from mage and the use thereof |
| 02/13/2002 | EP1179005A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy |
| 02/13/2002 | EP1178999A2 L-ribo-lna analogues |
| 02/13/2002 | EP1178993A1 Thiazoloderiatives and pharmaceutical compositions containing them |
| 02/13/2002 | EP1178988A1 Compounds and therapeutic methods |
| 02/13/2002 | EP1178981A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 02/13/2002 | EP1178977A1 Ion channel modulating agents |
| 02/13/2002 | EP1178971A1 Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
| 02/13/2002 | EP1178969A1 Gastrin and cholecystokinin receptor ligands |
| 02/13/2002 | EP1178967A1 Quinoline derivatives as inhibitors of mek enzymes |
| 02/13/2002 | EP1178966A1 Quinoline derivatives as inhibitors of mek enzymes |
| 02/13/2002 | EP1178965A1 Quinoline derivatives as inhibitors of mek enzymes |
| 02/13/2002 | EP1178963A1 Ion channel modulating agents |
| 02/13/2002 | EP1178960A1 Vitamin d analogues and their pharmaceutical use |
| 02/13/2002 | EP1178959A1 Alpha-amino-beta-sulfonyl hydroxamic acid compounds |
| 02/13/2002 | EP1178958A2 N-cyanomethyl amides as protease inhibitors |
| 02/13/2002 | EP1178954A1 A structure-based approach to design inhibitors of protein-processivity factor interactions |
| 02/13/2002 | EP1178952A1 NOVEL INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-$g(a) MODULATORS, SYNTHESES OF SAID MODULATORS AND METHODS OF USING SAID MODULATORS |
| 02/13/2002 | EP1178848A1 Bioadhesive hydrogels with functionalized degradable crosslinks |
| 02/13/2002 | EP1178831A1 Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound |
| 02/13/2002 | EP1178828A1 Death domain containing receptor 4 |
| 02/13/2002 | EP1178826A1 Immunotherapy of b-cell malignancies using anti-cd22 antibodies |
| 02/13/2002 | EP1178825A2 Adjuvant combination formulations |
| 02/13/2002 | EP1178823A2 New vaccine formulations - 1 |
| 02/13/2002 | EP1178822A2 New vaccine formulations - 2 |
| 02/13/2002 | EP1178815A1 Death domain containing receptors |
| 02/13/2002 | EP1178810A2 Use of bisphosphonic acids for treating angiogenesis |
| 02/13/2002 | EP1178804A2 Use of topical azathioprine to treat inflammatory bowel disorders |